Ethylphenidate (EPH) is a psychostimulant and a close analog of methylphenidate.
However, considering the close similarities between ethylphenidate and methylphenidate and the fact that methylphenidate, like cocaine, actually does not primarily act as a “classical” reuptake inhibitor, but rather as an “inverse agonist at the DAT” (also called a “negative allosteric modulator at the DAT”), it is at least very likely that ethylphenidate also primarily acts as an inverse DAT agonist instead of (or at least only secondarily) as a classical reuptake inhibitor (which could be called a “competitive antagonist at the DAT” using a similar terminology as “negative allosteric modulator at the DAT”, which per definition means that its mechanism is non-competitive).
There have been anecdotal reports of a perforated septum resulting from even just a few uses of ethylphenidate by insufflation (snorting). Some users also report the drug is extremely painful to insufflate.
Ethylphenidate metabolizes into methylphenidate and ritalinic acid.
Tiny amounts of ethylphenidate can be formed in vivo when alcohol (also known formally as ethanol) and methylphenidate are coingested, via hepatic transesterification.
Ethylphenidate formation appears to be more common when large quantities of methylphenidate and alcohol are consumed at the same time, such as in non-medical use or overdose scenarios.
However, the transesterfication process of methylphenidate to EPH, as tested in mice liver, was dominant in the inactive (−)-enantiomer but showed a prolonged and increased maximal plasma concentration of the active (+)-enantiomer of methylphenidate. Additionally, only a few percent of the consumed methylphenidate is converted to ethylphenidate.
This carboxylesterase-dependent transesterification process is also known to occur when cocaine and alcohol are consumed together, forming cocaethylene.
All available data on ethylphenidate’s pharmacokinetics are drawn from studies conducted on rodents. Ethylphenidate is more selective to the
ETHYLPHENIDATE CRYSTALS is a potent psychostimulant that acts as both a dopamine reuptake inhibitor and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft.
ETHYLPHENIDATE CRYSTALS Similar in structure to methylphenidate (Ritalin), EPH is available for research purposes only . Acting as a psychostimulant, Ethylphenidate affects the norepinephrine and dopamine transmitters, which results in a feeling of euphoria.
This product is sold to researchers in powder, crystal and pellet form for in vitro use only. It is not meant for human consumption.
There is still much to be learned about this chemical, although we do know that it has some psycho-stimulant effects.
Early test results show that it raises norepinephrine and dopamine neurotransmitter levels in the brain by inhibiting dopamine reuptake and norepinephrine reuptake in the brain.
This chemical’s molecular formula is C15H21NO2, while Its IUPAC listing is ethyl 2-phenyl-3-piperidin-2-ylacetate.
This product is sold only for research uses in laboratory settings.
We sell the finest product in the market, ethylphenidate Powder, Crystal and glass!
There is still much to be learned about this chemical, although we do know that it has some psycho-stimulant effects. Early test results show that it raises norepinephrine and dopamine neurotransmitter levels in the brain by inhibiting dopamine reuptake and norepinephrine reuptake in the brain.
This chemical’s molecular formula is C15H21NO2, while Its IUPAC listing is ethyl 2-phenyl-3-piperidin-2-ylacetate. Ethylphenidate’s CAS is 57413-43-1. Because of how potent this chemical is, we recommend that safety gear be worn at all times while working with it.